Mid American Wealth Advisory Group Inc. purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 8,311 shares of the company's stock, valued at approximately $270,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Vaxcyte in the second quarter worth $341,000. J.Safra Asset Management Corp lifted its position in shares of Vaxcyte by 18.5% in the second quarter. J.Safra Asset Management Corp now owns 3,746 shares of the company's stock worth $122,000 after buying an additional 585 shares during the last quarter. TD Asset Management Inc lifted its position in shares of Vaxcyte by 77.8% in the second quarter. TD Asset Management Inc now owns 539,784 shares of the company's stock worth $17,548,000 after buying an additional 236,188 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in shares of Vaxcyte during the 2nd quarter worth about $245,000. Finally, CWM LLC increased its holdings in shares of Vaxcyte by 197.3% during the 2nd quarter. CWM LLC now owns 1,680 shares of the company's stock valued at $55,000 after acquiring an additional 1,115 shares during the last quarter. Institutional investors own 96.78% of the company's stock.
Vaxcyte Stock Up 1.2%
Shares of PCVX stock opened at $42.90 on Tuesday. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $116.00. The firm has a market cap of $5.57 billion, a PE ratio of -10.44 and a beta of 1.12. The stock has a 50 day moving average of $34.86 and a 200-day moving average of $33.82.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period last year, the company earned ($1.10) EPS. As a group, equities analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently weighed in on PCVX shares. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, September 12th. They issued a "neutral" rating and a $38.00 target price for the company. Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $106.25.
Get Our Latest Analysis on PCVX
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
